Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle

Temporally and spatially constrained Hedgehog (Hh) signaling regulates cyclic growth of hair follicle epithelium while constitutive Hh signaling drives the development of basal cell carcinomas (BCCs), the most common cancers in humans. Using mice engineered to conditionally express the Hh effector G...

Full description

Saved in:
Bibliographic Details
Published inGenes & development Vol. 19; no. 2; pp. 214 - 223
Main Authors Hutchin, Mark E, Kariapper, Muhammed S T, Grachtchouk, Marina, Wang, Aiqin, Wei, Lebing, Cummings, Donelle, Liu, Jianhong, Michael, L Evan, Glick, Adam, Dlugosz, Andrzej A
Format Journal Article
LanguageEnglish
Published United States Cold Spring Harbor Laboratory Press 15.01.2005
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Temporally and spatially constrained Hedgehog (Hh) signaling regulates cyclic growth of hair follicle epithelium while constitutive Hh signaling drives the development of basal cell carcinomas (BCCs), the most common cancers in humans. Using mice engineered to conditionally express the Hh effector Gli2, we show that continued Hh signaling is required for growth of established BCCs. Transgene inactivation led to BCC regression accompanied by reduced tumor cell proliferation and increased apoptosis, leaving behind a small subset of nonproliferative cells that could form tumors upon transgene reactivation. Nearly all BCCs arose from hair follicles, which harbor cutaneous epithelial stem cells, and reconstitution of regressing tumor cells with an inductive mesenchyme led to multilineage differentiation and hair follicle formation. Our data reveal that continued Hh signaling is required for proliferation and survival of established BCCs, provide compelling support for the concept that these tumors represent an aberrant form of follicle organogenesis, and uncover potential limitations to treating BCCs using Hh pathway inhibitors.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
E-MAIL dlugosza@umich.edu ; FAX (734) 763-4575.
Article published online ahead of print. Article and publication date are at http://www.genesdev.org/cgi/doi/10.1101/gad.1258705.
Corresponding author.
ISSN:0890-9369
1549-5477
DOI:10.1101/gad.1258705